Is Rituxan FDA approved for mantle cell lymphoma?

October 19, 2012 – The U.S. Food and Drug Administration (FDA) approved a 90-minute infusion for rituximab (Rituxan) starting at Cycle 2 for patients with non-Hodgkin’s lymphoma (NHL) who did not experience a grade 3 or 4 infusion-related adverse reaction during Cycle 1.

What is the best treatment for mantle cell lymphoma?

Chemotherapy, often followed by stem cell transplant, remains the cornerstone of front-line treatment for patients with mantle cell lymphoma.

Are there a new treatments for mantle cell lymphoma?

Now there’s a new option for those patients: Tecartus, a personalized therapy made from a patient’s own immune cells. The one-time treatment was approved by the FDA to treat patients who have not responded or have relapsed following other kinds of treatment.

When was Rituxan approved by FDA?

Rituxan was approved in November 1997 and is manufactured by Genentech. With the Truxima approval, the FDA has approved 15 biosimiliars.

Can you go into remission with mantle cell lymphoma?

Your treatment for mantle cell lymphoma may put you into remission, which means you no longer have signs of cancer. But after a while, your cancer may return. If it does, it doesn’t mean you’re out of options. Your doctor may suggest other medicines that may work for you.

What is Rituxan FDA approved for?

On December 2, 2021, the FDA approved rituximab (brand name Rituxan) in combination with chemotherapy for pediatric patients 6 months to 18 years with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

What drug class is Rituxan?

Rituximab injection (Rituxan) is used to treat pemphigus vulgaris (a condition that causes painful blisters on the skin and the lining the mouth, nose, throat and genitals). Rituximab injection products are in a class of medications called monoclonal antibodies.